Company Description

Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist.

Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve.

We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale.

We are advancing three late-stage cardiovascular therapies in indications for which no approved therapies currently exist.

Kardigan, Inc.

Country	United States
Founded	2023
Industry	Biotechnology
Sector	Healthcare
Employees	241
CEO	Tassos Gianakakos

Contact Details

Address: 506 Carnegie Center Drive, Suite 201 Princeton, NJ 08540 United States
Phone	(415) 573-3220
Website	kardigan.bio

Stock Details

Ticker Symbol	KARD
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	2123613

Key Executives

Name	Position
Tassos Gianakakos	Chief Executive Officer, Director, and Chair
Brianne Puglisi	Chief Financial Officer
Jay Edelberg	Chief Medical Officer
Andy Pasternak	Chief Strategy Officer
John B. Moriarty, Jr.	Chief Legal Officer and Corporate Secretary
Paul Berns	Director
Douglas Giordano	Director
David Meeker, M.D.	Director
Kim Popovits	Director
Tim Walbert	Director

Latest SEC Filings

Date	Type	Title
May 26, 2026	S-1	General form for registration of securities under the Securities Act of 1933
May 4, 2026	DRS/A	[Amend] [Cover] Draft Registration Statement
Mar 26, 2026	DRS	[Cover] Draft Registration Statement

View All SEC Filings